Drugs / XNW5004
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06022757 | Sep 2023 → Aug 2028 expected | cervical cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, prostate cancer +2 | Evopoint Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06702995 | Apr 2023 → May 2026 overdue | castration-resistant prostate carcinoma | Evopoint Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06558513 | Aug 2021 → Aug 2025 | high grade malignant neoplasm, lymphoma | Evopoint Biosciences Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07545603 | Feb 2026 → Dec 2027 expected | follicular lymphoma | Evopoint Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06702605 | Nov 2024 → Jan 2027 expected | peripheral T-cell lymphoma, not otherwise specified | Evopoint Biosciences Inc. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06776952 | Apr 2025 → Jan 2028 expected | peripheral T-cell lymphoma, not otherwise specified | Evopoint Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XNW5004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06702605 ↗ |
| Action | Inhibit | “XNW5004 an EZH2 inhibitor, BID, administered in continuous” NCT06022757 ↗ |
| Route | Oral | “XNW5004 will be administered orally as tablets.” NCT06702605 ↗ |
| Target | EZH2 | “XNW5004 an EZH2 inhibitor, BID, administered in continuous” NCT06022757 ↗ |